Aim immunotech provides progress on advancement of ampligen® clinical development program for the treatment of pancreatic cancer

- ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with advanced pancreatic cancer

AIM Ratings Summary

AIM Quant Ranking